Zalviso

RSS

sufentanil

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Zalviso has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 27/09/2022

Authorisation details

Product details
Name
Zalviso
Agency product number
EMEA/H/C/002784
Active substance
sufentanil
International non-proprietary name (INN) or common name
sufentanil
Therapeutic area (MeSH)
Pain, Postoperative
Anatomical therapeutic chemical (ATC) code
N01AH03
Publication details
Marketing-authorisation holder
FGK Representative Service GmbH
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
18/09/2015
Contact address

Heimeranstrasse 35
80338 Munich
Germany

Product information

05/08/2022 Zalviso - EMEA/H/C/002784 - T/0017

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Anesthetics

Therapeutic indication

Zalviso is indicated for the management of acute moderate to severe post-operative pain in adult patients.

Assessment history

How useful was this page?

Add your rating
Average
1 rating